# Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines

> **NCT00891176** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 582 (actual)

## Conditions studied

- Neisseria Meningitidis
- Haemophilus Influenzae Type b

## Interventions

- **BIOLOGICAL:** MenitorixTM
- **BIOLOGICAL:** Pneumococcal conjugate vaccine GSK1024850A
- **BIOLOGICAL:** PrevenarTM
- **BIOLOGICAL:** MeningitecTM
- **BIOLOGICAL:** NeisVac-CTM
- **BIOLOGICAL:** InfanrixTM hexa
- **BIOLOGICAL:** InfanrixTM penta
- **BIOLOGICAL:** InfanrixTM IPV/Hib
- **BIOLOGICAL:** InfanrixTM IPV

## Key facts

- **NCT ID:** NCT00891176
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05-14
- **Primary completion:** 2012-11-21
- **Final completion:** 2012-11-21
- **Target enrollment:** 582 (ACTUAL)
- **Last updated:** 2018-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00891176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00891176, "Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT00891176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*